ADZYNMA Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to limited treatment availability for cTTP, high mortality rates in untreated patients, reliance on plasma exchange therapy, advancements in genetic disorder diagnosis, unmet needs in rare disease care.

The growth in the forecast period can be attributed to growth in rare disease awareness programs, improved affordability of targeted therapies, expansion of specialty treatment centers, rising genetic screening adoption, increased public healthcare funding. Major trends in the forecast period include growing focus on rare genetic blood disorders, increased access to cost-effective biologic therapies, expansion of pediatric and adult treatment coverage, rising importance of early genetic diagnosis, improved availability of targeted therapies.

The increasing prevalence of autoimmune disorders is expected to drive the growth of the ADZYNMA market in the coming years. Autoimmune disorders are conditions in which the immune system mistakenly attacks healthy tissues, resulting in chronic inflammation and damage to organs and bodily systems. The rising occurrence of these disorders is linked to a combination of genetic susceptibility, environmental influences, and lifestyle-related factors. ADZYNMA is a therapeutic agent designed to regulate immune responses in autoimmune conditions by targeting specific pathways that help reduce inflammation and limit tissue damage. For example, in July 2025, according to data from Public Health Scotland, a Scotland-based national organization, 470 newly diagnosed multiple sclerosis (MS) patients were added to the Scottish Multiple Sclerosis Register (SMSR) in 2024. Additionally, the proportion of newly diagnosed patients who received contact from an MS specialist nurse within 10 working days increased from 88.3% in 2023 to 93.3% in 2024. As a result, the growing prevalence of autoimmune disorders is contributing to the expansion of the ADZYNMA market.

Companies operating in the ADZYNMA market are increasingly focusing on advances in biologic drug development to strengthen their competitive position. These advancements include the development of monoclonal antibodies, fusion proteins, and recombinant biologics, which offer greater treatment precision and fewer side effects compared with conventional therapies. For instance, in November 2023, Takeda, a Japan-based biopharmaceutical company, announced that the U.S. Food and Drug Administration approved ADZYNMA (ADAMTS13, recombinant-krhn) for both prophylactic and on-demand treatment of adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP). As the first and only FDA-approved recombinant ADAMTS13 protein, ADZYNMA addresses a critical unmet need by replacing the deficient ADAMTS13 enzyme in patients with cTTP.

In February 2024, Takeda, a Japan-based biopharmaceutical company, entered into a partnership with Protagonist Therapeutics to develop and commercialize rusfertide. This collaboration builds on Takeda’s expertise in rare hematologic disorders, demonstrated by the recent FDA approval of ADZYNMA for the treatment of congenital thrombotic thrombocytopenic purpura. Protagonist Therapeutics is a US-based biopharmaceutical company specializing in peptide-based therapeutic development.

Major companies operating in the adzynma market are Takeda Pharmaceutical Company Limited.

North America was the largest region in the ADZYNMA market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adzynma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the adzynma market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have affected the adzynma market by increasing costs for imported biologic substances, formulation reagents, and quality control materials. These cost pressures have influenced pricing strategies in rare disease therapies, particularly in countries dependent on imported specialty medicines. Hospital and specialty pharmacy segments in regions such as asia-pacific and eastern europe face greater sensitivity to tariff changes. On the positive side, tariffs have supported local sourcing initiatives, incentivized regional manufacturing partnerships, and improved long-term access to essential treatments.

The adzynma market research report is one of a series of new reports that provides adzynma market statistics, including adzynma industry global market size, regional shares, competitors with a adzynma market share, detailed adzynma market segments, market trends and opportunities, and any further data you may need to thrive in the adzynma industry. This adzynma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Adzynma is a medication used to treat congenital thrombotic thrombocytopenic purpura (cTTP), a rare genetic disorder caused by mutations in the ADAMTS13 gene, in both pediatric and adult patients. It is developed to offer a more cost-effective option while maintaining comparable safety and effectiveness, thereby improving access to this life-saving therapy.

The main indication categories for Adzynma include autoimmune diseases, inflammatory diseases, and others. Autoimmune diseases arise when the immune system mistakenly attacks the body’s own tissues, resulting in inflammation and damage to various organs or systems. Adzynma is distributed through hospitals and clinics as well as retail and specialty pharmacies, and it is used by end users including adult and pediatric patients.

The ADZYNMA market consists of sales of biologic therapies for autoimmune and inflammatory diseases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.